Bristol Myers Squibb (BMY) Net Cash Flow Growth (3y) (2012 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (BMY) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 38.53% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -51.84% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -11.43% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 1.06% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 106.37% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 18.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.43% |
| Mar 31, 2026 | -26.50% |
| Dec 31, 2025 | -84.99% |
| Sep 30, 2025 | 45.21% |
| Jun 30, 2025 | 44.84% |
| Mar 31, 2025 | 31.32% |
| Dec 31, 2024 | 74.32% |
| Sep 30, 2024 | -15.40% |
| Jun 30, 2024 | -277.98% |
| Mar 31, 2024 | 16.03% |
| Dec 31, 2023 | 40.59% |
| Sep 30, 2023 | -15.39% |
| Jun 30, 2023 | -29.10% |
| Mar 31, 2023 | -27.71% |
| Dec 31, 2022 | 27.49% |
| Sep 30, 2022 | -50.29% |
| Jun 30, 2022 | -27.52% |
| Mar 31, 2022 | -83.19% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | 82.64% |